Hospitalisation costs of sinonasal cancer: Results from the Italian hospital discharge registry (2001-2018)

Abstract

Objective: This paper assesses hospital costs associated with sinonasal cancer (SNC) in Italy and evaluates related time trends.
Methods: All Italian hospitalizations treating patients with a diagnosis of SNC (N = 29,355) were extracted from the National Hospital Discharge Registry. Data refer to patients discharged from public and private hospitals between 2001 and 2018. Hospitalization cost, admission rate, length of stay and other hospitalization-level variables were used as the main outcome variables. Information on the relative disease intensity per hospitalization was used to specifically allocate total hospitalization costs to SNC medical resources.
Results: Over the 2001-2018 period, Italian hospitals have treated 1,631 admissions with SNC every year, on average. The mean annual hospitalization cost across all hospitals was 5,502,909 €, or 3,374 € per admission, and 60.0% of these costs were attributable to SNC only. Patient age at discharge (from 62 to 63 years), percentage of surgical procedures (from 29.3% to 46.8%) and of urgent cases (from 13.5% to 16.5%) increased over time. The percentage of costs attributable to SNC followed an inverted U-shaped pattern reaching the minimum level in 2006; conversely, mortality rose until 2007 then decreased steadily.
Conclusions: Good progress has been made in SNC treatments. Endoscopic techniques represent one of the most important advances in this field, reducing morbidity and hospital length of stay while keeping similar survival rates. Policies aimed at monitoring workers most exposed to SNC risk and at standardizing hospital treatments could help Public Health Institutions to plan optimal prevention policies.

Keywords

Sinonasal cancer / Sinonasal cancer burden / Hospital discharge data

References

[1] Cardesa A, Slootweg PJ, Gale N, et al. Pathology of the Head and Neck. Springer; 2017 Feb 8. https://doi.org/10.1007/978-3-662-49672-5

[2] Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head & Neck. 2012; 34(6): 877-85. PMid:22127982. https://doi.org/10.1002/hed.21830

[3] Binazzi A, Ferrante P, Marinaccio A. Occupational exposure and sinonasal cancer: a systematic review and meta-analysis. BMC Can-cer. 2015; 15(1): 1-7. PMid:25885319. https://doi.org/10.1186/s12885-015-1042-2

[4] Franchi A, Miligi L, Palomba A, et al. Sinonasal carcinomas: recent advances in molecular and phenotypic characterization and their clin-ical implications. Critical Reviews in Oncology/Hematology. 2011; 79(3): 265-77. PMid:20870420. https://doi.org/10.1016/j.critrevonc.2010.08.002

[5] Marinaccio A, Binazzi A, Bonafede M. Il Registro Nazionale dei Tumori Naso-Sinusali (ReNaTuNS)-Primo rapporto. 2016.

[6] Rhee CS, Won TB, Lee CH, et al. Adenoid cystic carcinoma of the sinonasal tract: treatment results. The Laryngoscope. 2006; 116(6): 982-6. PMid:16735899. https://doi.org/10.1097/01.mlg.0000216900.03188.48

[7] Kawaguchi M, Kato H, Tomita H, et al. Imaging characteristics of ma-lignant sinonasal tumors. Journal of Clinical Medicine. 2017; 6(12): 116. PMid:29211048. https://doi.org/10.3390/jcm6120116

[8] Youlden DR, Cramb SM, Peters S, et al. International comparisons of the incidence and mortality of sinonasal cancer. Cancer Epidemi-ology. 2013; 37(6): 770-9. PMid:24138871. https://doi.org/10.1016/j.canep.2013.09.014

[9] Sjöstedt S, Jensen DH, Jakobsen KK, et al. Incidence and survival in sinonasal carcinoma: a Danish population-based, nationwide study from 1980 to 2014. Acta Oncologica. 2018; 57(9): 1152-8. https://doi.org/10.1080/0284186X.2018.1454603

[10] Unsal AA, Kılıç S, Dubal PM, et al. A population-based com-parison of European and North American sinonasal cancer sur-vival. Auris Nasus Larynx. 2018; 45(4): 815-24. PMid:29056464. https://doi.org/10.1016/j.anl.2017.09.009

[11] Dutta R, Dubal PM, Svider PF, et al. Sinonasal malignancies: a population-based analysis of site-specific incidence and survival. The Laryngoscope. 2015; 125(11): 2491-7. PMid:26228792. https://doi.org/10.1002/lary.25465

[12] Van Dijk BA, Gatta G, Capocaccia R, et al. Rare cancers of the head and neck area in Europe. European Journal of Cancer. 2012; 48(6):783-96. PMid:22051735. https://doi.org/10.1016/j.ejca.2011.08.021

[13] Siew SS, Kauppinen T, Kyyrönen P, et al. Occupational exposure to wood dust and formaldehyde and risk of nasal, nasopharyngeal, and lung cancer among Finnish men. Cancer Management and Research. 2012; 4: 223. PMid:22904644. https://doi.org/10.2147/CMAR.S30684

[14] Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associ-ated with human cancers. Journal of the National Cancer Institute. 2011; 103(24): 1827-39. PMid:22158127. https://doi.org/10.1093/jnci/djr483

[15] Straif K, Benbrahim-Tallaa L, Baan R, et al. A review of human carcinogens-part C: metals, arsenic, dusts, and fibres. The Lancet. Oncology. 2009; 10(5): 453-4. https://doi.org/10.1016/S1470-2045(09)70134-2

[16] Kauppinen T, Vincent R, Liukkonen T, et al. Occupational exposure to inhalable wood dust in the member states of the European Union. The Annals of Occupational Hygiene. 2006; 50(6): 549-61.

[17] Scarselli A, Binazzi A, Ferrante P, et al. Occupational exposure levels to wood dust in Italy, 1996-2006. Occupational and Environ-mental Medicine. 2008; 65(8): 567-74. PMid:18086698. https://doi.org/10.1136/oem.2007.036350

[18] Robin TP, Jones BL, Gordon OM, et al. A comprehensive com-parative analysis of treatment modalities for sinonasal malignan-cies. Cancer. 2017; 123(16): 3040-9. PMid:28369832. https://doi.org/10.1002/cncr.30686

[19] Su SY, Kupferman ME, DeMonte F, et al. Endoscopic resection of sinonasal cancers. Current Oncology Reports. 2014; 16(2): 369. PMid:24445501. https://doi.org/10.1007/s11912-013-0369-6

[20] Subramanian N, Marchi F, Carobbio AL, et al. Induction chemother-apy in sinonasal malignancies: A review of literature. Journal of Head & Neck Physicians and Surgeons. 2019; 7(2): 52. https://doi.org/10.4103/jhnps.jhnps_6_20

[21] Ferrante P.Costs of asbestosis and silicosis hospitalization in Italy ( 2001-2018). International Archives of Occupational and Environ-mental Health. 2021; 1-9. PMid:33404732. https://doi.org/10.1007/s00420-020-01637-z

[22] Ferrante P. Asbestosis and silicosis hospitalizations in Italy (2001-2015): results from the National hospital discharge registry. Euro-pean Journal of Public Health. 2019; 29(5): 876-82. PMid:30753424. https://doi.org/10.1093/eurpub/ckz003

[23] Pierpaolo F.Hospitalisation costs of malignant mesothelioma: results from the Italian hospital discharge registry (2001-2018). BMJ Open. 2021; 11(8): e046456. PMid:34373297. https://doi.org/10.1136/bmjopen-2020-046456

[24] Giorgetti R. Legislazione e organizzazione del servizio sanitario. Maggioli Editore; 2016.

[25] Bellavia M, Tomasello G, Damiani P, et al. Towards an improvement of hospital services and streamlining of health care costs: the DRG analysis in Italy. Iranian Journal of Public Health. 2012; 41(7): 1.

[26] Ministero della Salute. Rapporto annuale sull’attività di ricovero ospedaliero. Dati SDO 2018; Luglio 2020.

[27] Beckett WS. Occupational respiratory diseases. New England Jour-nal of Medicine. 2000; 342(6): 406-13. PMid:10666432. https://doi.org/10.1056/NEJM200002103420607

[28] Passalacqua F, Zaetta C, Janssone R, et al.Pellets in Southern Europe. The state of the art of pellets utilisation in Southern Europe. New per-spectives of pellets from agri-residues. In 2nd World Conference on Biomass for Energy, Industry and Climate Protection, ETA-Florence, Florence, Italy, and WIP-Munich, Munich, Germany 2004 May 10.

[29] Pettenella D, Klöhn S, Brun F, et al. Economic integration of urban consumers’ demand and rural forestry production. Italy’s Country Report, COST Action E. 2004; 30.

[30] Industrial minerals association-Europe (IMA-Europe).Available from: https://www.ima-europe.eu/content/occupational-exposure-limits-%E2%80%93-respirable-dust-%E2%80%93-full-table (26 December 2018, date last accessed).

[31] Manoukian PD, Wyatt JR, Leopold DA, et al. Recent trends in utilization of procedures in otolaryngologyhead and neck surgery. The Laryngoscope. 1997; 107(4): 472-7. PMid:9111376. https://doi.org/10.1097/00005537-199704000-00009

[32] Carlton DA, David Beahm D, Chiu AG. Sinonasal malignancies: Endoscopic treatment outcomes. Laryngoscope Investigative Oto-laryngology. 2019; 4(2): 259-63. PMid:31024998. https://doi.org/10.1002/lio2.249

[33] Forastiere AA, Ang KK, Brizel DN. Head and Neck Cancers. Na-tional Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-v. 2.2008.

[34] Lund VJ, Stammberger H, Nicolai P, et al. European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinol Suppl. 2010; 22(2):1-43.

[35] Gangl K, Nemec S, Altorjai G, et al. Prognostic survival value of retropharyngeal lymph node involvement in sinonasal tumors: A retrospective, descriptive, and exploratory study. Head & Neck. 2017; 39(7): 1421-1427. PMid:28452184. https://doi.org/10.1002/hed.24782.